Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risks of estrogens and progestogens

M L'Hermite1

  • 1Service de Gynécologie-Obstétrique, Hôpital Universitaire Brugmann, Université Libre de Bruxelles, Belgium.

Maturitas
|September 1, 1990
PubMed
Summary

No abstract available in PubMed .

Keywords:
BiologyBreast CancerCancerCarbohydrate Metabolic EffectsCardiovascular EffectsCerebrovascular EffectsChlormadinone AcetateContraceptionContraceptive AgentsContraceptive Agents, EstrogenContraceptive Agents, FemaleContraceptive Agents, ProgestinCyproterone AcetateDemographic FactorsDesogestrelDiseasesEmbolismEndocrine SystemEndometrial CancerEstradiolEstriolEstrogenic Substances, ConjugatedEstrogensEstroneEthinyl EstradiolFamily PlanningGallbladder DiseasesGestodeneGlucose Metabolism EffectsHematological EffectsHemic SystemHormone AntagonistsHormonesHypertensionLevonorgestrelLipid Metabolic EffectsLipidsLiterature ReviewLynestrenolMedroxyprogesterone AcetateMenopauseMetabolic EffectsMortality--womenNeoplasmsNorethindroneNorgestimatePhysiologyPopulationPopulation DynamicsReproductionRisk FactorsSerum Protein EffectsThromboembolismVascular Diseases

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use.

Climacteric : the journal of the International Menopause Society·2017
Same author

Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.

Climacteric : the journal of the International Menopause Society·2017
Same author

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.

Climacteric : the journal of the International Menopause Society·2013
Same author

[Asphyxiating thoracic dysplasia (Jeune syndrome): about two cases].

Journal de gynecologie, obstetrique et biologie de la reproduction·2009
Same author

Small cell carcinoma of the ovary successfully treated with radiotherapy only after surgery: case report.

European journal of gynaecological oncology·2008
Same author

The long-term tolerability and efficacy of OESCLIM: results of a 1-year study.

Maturitas·2000
Same journal

Digital twins in menopause: a roadmap for integrating endocrine dynamics, multisystem physiology, and precision medicine.

Maturitas·2026
Same journal

Testosterone therapy in women: Keeping pace with the evidence.

Maturitas·2026
Same journal

Diagnosis and management of androgen excess presenting after menopause.

Maturitas·2026
Same journal

Domain-specific severity of menopausal symptoms and emotional eating in midlife women.

Maturitas·2026
Same journal

Energy-based therapies for vulvar lichen sclerosus: A systematic review of randomized controlled trials.

Maturitas·2026
Same journal

Change of sexual activity and its relation to the quality of life in older people: Cognition of Older People, Education, Recreational Activities, NutritIon, Comorbidities, fUnctional Capacity Studies (COPERNICUS).

Maturitas·2026
See all related articles